Company Overview of Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. is a biotechnology company that develops new medicines for destructive autoimmune diseases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The company was founded in 2014 and is based in Cambridge, Massachusetts. As of April 1, 2016, Padlock Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
200 Cambridge Park Drive
Cambridge, MA 02140
Founded in 2014
Key Executives for Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Padlock Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.